Volume : 09, Issue : 06, June – 2022
Title:
59.ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF MIRABEGRON AND SOLIFENACIN IN BULK AND PHARMACEUTICAL DOSAGE FORM BY RP-HPLC
Authors :
K. V. L. D. Spandana, N. J. P. Subhashini*
Abstract :
A rapid stability-indicating RP-HPLC was developed and validated for the estimation of Mirabegron and Solifenacin combination in bulk and tablet dosage form using Thermo C18 column (250 x 4.6 mm,5m) as a stationary phase and a mixture solution of 0.1 percent Diazanium sulphate buffer: Acetonitrile (60:40v/v) as the mobile phase at a flow rate of 1 ml/min. A photodiode array detector was used for detection at 246 nm. The linearity, sensitivity, selectivity, robustness, specificity, precision, and accuracy were all determined.
The peak area response-concentration curve was rectilinear over the concentration ranges of 25-75 g/ml (Mirabegron) and 2.5-7.5 g/ml (Solifenacin), with quantitation limits of 0.793 g/ml (Mirabegron) and 0.307 g/ml (Solifenacin). The proposed method was validated for the simultaneous determination of mifepristone and misoprostol in combined tablet dosage form. In comparison to previously reported RP-HPLC methods, the performance of the proposed method was found to be rapid and cost-effective. The developed and validated stability-indicating RP-HPLC method was suitable for quality control and drug analysis.
Key words: RP-HPLC, stability-indicating, tablet dosage form
Cite This Article:
Please cite this article in press Konduru Spandana et al, Analytical Method Development And Validation For The Simultaneous Estimation Of Mirabegron And Solifenacin In Bulk And Pharmaceutical Dosage Form By RP-HPLC., Indo Am. J. P. Sci, 2022; 09(6).,
Number of Downloads : 10
References:
1) Sacco E, Pinto F, Bassi P. Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. International Urogynecology Journal. 2008 Apr;19(4):583-98.
2) Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O. Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl) amino] ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function. Journal of Pharmacology and Experimental Therapeutics. 2007 May 1;321(2):642-7.
3) Dawood O, El-Zawahry A. Mirabegron. InStatPearls [Internet] 2020 Jul 15. StatPearls Publishing.
4) Kreder KJ. Solifenacin. Urologic Clinics. 2006 Nov 1;33(4):483-90.
5) Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). European urology. 2015 Mar 1;67(3):577-88.
6) Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II). European urology. 2018 Oct 1;74(4):501-9.
7) Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II). European urology. 2018 Oct 1;74(4):501-9.
8) Krauwinkel WJ, Kerbusch VM, Meijer J, Tretter R, Strabach G, Van Gelderen EM. Evaluation of the pharmacokinetic interaction between the β3‐adrenoceptor agonist mirabegron and the muscarinic receptor antagonist solifenacin in healthy subjects. Clinical Pharmacology in Drug Development. 2013 Jul;2(3):255-63.
9) Desai N, Hussen SS, Vasanthraju SG, Karthik A, Udupa N. Development & validation of stability indicating HPLC method for determination of solifenacin in bulk formulations. International Journal of Pharmacy and pharmaceutical sciences. 2011;3(1):70-4.
10) Shaik RP, Puttagunta SB, Kothapalli Bannoth C, Challa BS. Analytical method development and validation of solifenacin in pharmaceutical dosage forms by RP-HPLC. International Scholarly Research Notices. 2014;2014.
11) Wadie M, Abdel-Moety EM, Rezk MR, Tantawy MA. Eco-friendly chiral HPLC method for determination of alfuzosin enantiomers and solifenacin in their newly pharmaceutical combination: Method optimization via central composite design. Microchemical Journal. 2021 Jun 1;165:106095.
12) Tantawy MA, Weshahy SA, Wadie M, Rezk MR. A novel HPLC-DAD method for simultaneous determination of alfuzosin and solifenacin along with their official impurities induced via a stress stability study; investigation of their degradation kinetics. Analytical Methods. 2020;12(26):3368-75.
13) Desai D, Patel G, Shukla N, Rajput S. Development and validation of stability-indicating HPLC method for solifenacin succinate: isolation and identification of major base degradation product. Acta Chromatographica. 2012 Sep 1;24(3):399-418.
14) Israel DS, Krishnachaitanya K, Gowrisankar D. RP-HPLC method for the estimation of tamsulosin and solifenacin in bulk and its dosage forms. International Journal of Pharmaceutical Sciences and Research. 2013 Nov 1;4(11):4343.
15) Reddy BV, Reddy BS, Raman NV, Reddy KS, Rambabu C. Development and validation of a specific stability indicating high performance liquid chromatographic methods for related compounds and assay of solifenacin succinate. Journal of chemistry. 2012;2013.
16) Bhavana V, Kumar HT, Rao SY, Rao VP. RP-HPLC method for estimation of solifenacin succinate in API and tablet dosage form. Asian Journal of Pharmaceutical Analysis. 2019;9(3):118-22.
17) El-Henawee MM, Abd El-Hay SS, Attala K, Eissa MS. Smart UV spectrophotometric methods based on simple mathematical filtration and classical methods for the simultaneous determination of tamsulosin and solifenacin: A comparative study of efficacy and spectral resolution. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2021 Feb 15;247:119151.
18) Alia Afra S, Rameeja S, Madhavi R, Venkataramanamma C, Divya G, Srilakshmi Y, Gobinath M, Saravanan D. A new spectrophotometric method for the determination of Solifenacin in pure form and in pharmaceutical formulations. Int. J. Res. Pharm. Sci. 2013;4:221-5.
19) Teja GD, Dasu CD, Srinivasa BP, Ravisankar P. Quantitative analysis of solifenacin succinate in pharmaceutical dosage form using UV absorption spectroscopy. J Chem Pharm Sci. 2013;6:195-8.
20) Papanna RK, Kanakapura B, Gowda SB, Basavaraju M, Puttegowda VK. Determination of Solifenacin Succinate in Pure and Pharmaceutical Dosage forms by Spectrophotometry. Journal of Analytical Chemistry. 2021 Nov;76(11):1262-70.
21) Tantawy MA, Weshahy SA, Wadie M, Rezk MR. Stability-indicating HPTLC method for the simultaneous detection and quantification of alfuzosin hydrochloride, solifenacin succinate along with four of their official impurities. Microchemical Journal. 2020 Sep 1;157:104905.
22) Shah DA, Tahilramani PJ, Patel VB, Chhalotiya U. High-Performance Thin-Layer Chromatographic Method for the Estimation of Mirabegron and Solifenacin Succinate Used in the Treatment of Overactive Bladder Syndrome. JPC–Journal of Planar Chromatography–Modern TLC. 2019 Aug;32(4):323-7.
23) Ravisankar P, Vidya VS, Nithya PD, Babu PS. Validated UV spectrophotometric method for quantitative determination of Mirabegron in bulk and Pharmaceutical dosage form. Der Pharmacia Lettre. 2016;8(14):96-103.
24) Spandana R, Rao RN, Reddy LS. Analytical method development and validation for the estimation of mirabegron in bulk and pharmaceutical dosage form by RP-HPLC. IAJPR. 2016;6(11):6880-7.
25) Suresh BK, Anusha N, Sravani AB. Analytical method development and validation for the estimation of Mirabegron in pure and its solid dosage form by UV spectrophotometric method. International Journal of Research in Pharmaceutical Sciences and Technology. 2020 Jul 20;1(4):146-50.
26) Roopa KP, Basavaiah K, Shankara BS, Mahesh B. Development and Validation of Spectrophotometric Methods for the Assay of Mirabegron in Bulk and Pharmaceutical Formulations. Journal of Applied Spectroscopy. 2021 Jan;87(6):1171-8.
27) Papanna RK, Gowda JB, Nagaraja P. An experimental design approach for optimization of spectrophotometric estimation of mirabegron in bulk and Pharmaceutical formulations. Journal of Analytical Chemistry. 2018 Sep;73(9):884-93.
28) Rao RN, Madhuri D, Reddy LS, Rani K, Tejaswini P, Gandla KS. Development and validation of derivative spectrophotometric method for estimation of Mirabegron in bulk and tablet dosage form. World Journal of Pharmaceutical Research. 2017 Sep 2;6(14):760-7.
29) Ramazani A, Rezaei M. RP-HPLC method development and validation for the quantitative estimation of mirabegron in extended-release tablets. Journal of Medicinal and Chemical Sciences. 2018;1(2):36-40.
30) Yehia AM, Sami I, Riad SA, El-Saharty YS. Comparison of Two Stability-Indicating Chromatographic Methods for the Determination of Mirabegron in Presence of Its Degradation Product. Chromatographia. 2017 Jan;80(1):99-107.
31) Kommineni V, Chowdary KP, Prasad SV. Development of a new stability indicating RP-HPLC method for simultaneous estimation of saxagliptine and dapagliflozin and its validation as per ICH guidelines. Int J Pharm Sci Res. 2017 Sep 1; 9:2920-32.
32) Kommineni V, Chowdary KP, Prasad SV. Development of a new stability indicating RP-HPLC method for simultaneous estimation of Metformin hydrochloride and Teneligliptin hydrobromide and its validation as per ich guidelines. Indo American Journal of Pharmaceutical Sciences. 2017 May 1;4(5):1109-19.
33) Guideline IH. Validation of analytical procedures: text and methodology. Q2 (R1). 2005 Nov;1(20):05.